©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2015; 21(36): 10314-10326
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10314
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10314
Potentiality of immunotherapy against hepatocellular carcinoma
Nobuhiro Tsuchiya, Yasushi Uemura, Tetsuya Nakatsura, Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan
Author contributions: Tsuchiya N and Nakatsura T drafted the manuscript; Sawada Y, Endo I and Uemura Y revised the manuscript.
Conflict-of-interest statement: Nakatsura T was supported by funding from Ono Pharmaceutical Co., Ltd. and is a scientific advisor for Ono Pharmaceutical Co., Ltd.
Conflict-of-interest statement: Nakatsura T was supported by funding from Ono Pharmaceutical Co., Ltd. and is a scientific advisor for Ono Pharmaceutical Co., Ltd.
Correspondence to: Tetsuya Nakatsura, MD, PhD, Chief, Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. tnakatsu@east.ncc.go.jp
Telephone: +81-4-71315490 Fax: +81-4-71336606
Received: March 17, 2015
Peer-review started: March 18, 2015
Peer-review started: March 18, 2015
First decision: April 13, 2015
First decision: April 13, 2015
Revised: May 21, 2015
Accepted: August 29, 2015
Article in press: August 31, 2015
Article in press: August 31, 2015
Published online: September 28, 2015
Processing time: 195 Days and 1.6 Hours
Peer-review started: March 18, 2015
Peer-review started: March 18, 2015
First decision: April 13, 2015
First decision: April 13, 2015
Revised: May 21, 2015
Accepted: August 29, 2015
Article in press: August 31, 2015
Article in press: August 31, 2015
Published online: September 28, 2015
Processing time: 195 Days and 1.6 Hours
Core Tip
Core tip: Hepatocellular carcinoma (HCC) has a high incidence and poor prognosis worldwide. Tumor immunotherapy is a promising novel therapy that will lead to improvements in both treatment-associated toxicity and outcome. This review summarizes current knowledge concerning the progress of immunotherapy for HCC.